KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Invested Capital: 2011-2025

Historic Invested Capital for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Sep 2025 value amounting to $1.1 billion.

  • Supernus Pharmaceuticals' Invested Capital rose 0.68% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 0.68%. This contributed to the annual value of $1.1 billion for FY2024, which is 11.25% up from last year.
  • According to the latest figures from Q3 2025, Supernus Pharmaceuticals' Invested Capital is $1.1 billion, which was down 0.28% from $1.1 billion recorded in Q2 2025.
  • In the past 5 years, Supernus Pharmaceuticals' Invested Capital ranged from a high of $1.3 billion in Q3 2022 and a low of $786.0 million during Q1 2021.
  • Over the past 3 years, Supernus Pharmaceuticals' median Invested Capital value was $1.0 billion (recorded in 2024), while the average stood at $1.0 billion.
  • Its Invested Capital has fluctuated over the past 5 years, first skyrocketed by 54.06% in 2021, then decreased by 24.29% in 2023.
  • Supernus Pharmaceuticals' Invested Capital (Quarterly) stood at $1.2 billion in 2021, then dropped by 24.08% to $907.3 million in 2022, then climbed by 7.30% to $973.6 million in 2023, then climbed by 11.25% to $1.1 billion in 2024, then grew by 0.68% to $1.1 billion in 2025.
  • Its Invested Capital stands at $1.1 billion for Q3 2025, versus $1.1 billion for Q2 2025 and $1.1 billion for Q1 2025.